Abstract. We examined the effects of a potent glutamate transporter inhibitor, (2S,3S)-3-{3-[4-(trifluoromethyl)benzoylamino]benzyloxy}aspartate (TFB-TBOA), on the expression of methamphetamine-induced behavioral sensitization in rats. Rats were intraperitoneally treated with 2 mg/ kg methamphetamine for 5 days and then challenged with 1 mg / kg methamphetamine. Intracerebroventricular administration of TFB-TBOA (0.1 nmol) 10 min before the challenge significantly facilitated the expression of behavioral sensitization. On the other hand, it had no effect on the locomotor activation elicited by the challenge with methamphetamine in repeatedsaline-treated (non-sensitized) rats. These results suggest that central glutamate transporters may play an inhibitory role in the expression of behavioral sensitization to methamphetamine.
Repeated intermittent administration of psychostimulants, such as amphetamine and methamphetamine (METH), to rodents leads to progressive augmentation of their locomotor activating effects, termed behavioral sensitization. Several lines of evidence suggest that the nucleus accumbens, which receives a prominent dopaminergic input from the ventral tegmental area, plays an essential role in the behavioral sensitization. In addition to the mesolimbic dopaminergic system, the glutamatergic system has been demonstrated to take part in the development and expression of behavioral sensitization (1) .
It is well recognized that extracellular glutamate is rapidly removed from the synaptic cleft by a family of Na + -dependent high affinity glutamate transporters in neurons (EAAC1 and EAAT4) and glial cells (GLT-1 and GLAST) in the brain, thereby maintaining physiological levels of glutamate (2) . Several studies have shown the altered expression and glutamate uptake activity of glutamate transporters by repeated administration of psychostimulants and other drugs of abuse (3, 4) . The reagents accelerating glutamate uptake reduced the induction of their behavioral sensitization as well as conditioned rewarding effects (5, 6) . Furthermore, we previously showed that the glutamate transporter inhibitor DL-threo-β-benzyloxyaspartate (DL-TBOA) facilitated the induction of morphine-induced conditioned place preference and the expression of morphine withdrawal symptoms (7). These results suggest that glutamate transporters may be involved in the addiction-related behaviors, including the induction of behavioral sensitization, to diverse drugs of abuse. However, the involvement of glutamate transporters in the expression of METH-induced behavioral sensitization has not been determined.
Recently, Shimamoto et al. synthesized a potent, nontransportable inhibitor for glutamate transporters, (2S,3S)-3-{3-[4-(trifluoromethyl)benzoylamino]benzyloxy}aspartate (TFB-TBOA), which is a derivative of L-TBOA (8) . TFB-TBOA is effective at low nanomolar concentrations for all subtypes and is highly selective for glutamate transporters. These properties suggest that TFB-TBOA is a suitable compound for behavioral studies. In the present study, we investigated the effects of intracerebroventricular (i.c.v.) administration of TFB-TBOA on the expression of METH-induced behavioral sensitization in rats.
Male Sprague-Dawley rats initially weighing 180 -220 g were used. They were kept at a constant ambient temperature of 24 ± 1°C under a 12-h light / dark cycle with free access to food and water. After their arrival, the rats were individually housed in plastic cages with woodchip bedding for at least 1 day before surgery. The experiments were conducted in accordance with the ethical guidelines of the Kyoto University animal experimentation committee and the Guiding Principles for the Care and Use of Laboratory Animals approved by The Japanese Pharmacological Society.
For i.c.v. administration, under pentobarbital (50 mg / kg, intraperitoneally (i.p.)) anesthesia, a stainless steel guide cannula (o.d. 0.7 mm) was implanted on the right side at coordinates of 0.8-mm caudal to the bregma, 1.5-mm lateral to the midline, and 2.0-mm below the surface of the skull. After surgery, the rats were individually returned to their cages and left to recover for at least 5 days before the experiments.
For induction of METH sensitization, rats were placed in the locomotor activity chamber consisting of a circular corridor (13.2 cm in height, 8 cm in width and 16 cm in external diameter) and acclimatized for 60 min. The activity chamber was enclosed by a sound-and light-attenuated box. During the induction phase, rats were i.p. injected with saline or DL-methamphetamine hydrochloride (METH; Dainippon Pharmaceutical Co., Osaka), which was freshly dissolved in saline each day, at a dose of 2 mg / kg in a volume of 1 ml / kg and then confined to the chamber for 2 h. This procedure was repeated daily for 5 consecutive days. After 3 days of withdrawal, rats were again placed in the chamber, acclimatized for 60 min, and then i.c.v. administered with vehicle (1% dimethyl sulfoxide in phosphatebuffered saline) or TFB-TBOA (gift from Dr. Keiko Shimamoto of the Suntory Institute of Bioorganic Research, Osaka) at a dose of 0.1 nmol. For i.c.v. administration, an injection cannula (o.d. 0.35 mm) was inserted into the right lateral ventricle just 5.0 mm below the surface of the skull when attached to the guide cannula. I.c.v. administration was carried out in a volume of 5 µl at a constant rate of 5 µl / 30 s. The injection cannula was left in place for an additional 30 s to prevent backflow. Because, in preliminary experiments, i.c.v. administration of TFB-TBOA at a dose of 1 nmol to naive rats elicited irritability, motor hyperexcitability and / or convulsion immediately or soon after i.c.v. administration, we used a dose of 0.1 nmol.
Ten minutes after the i.c.v. administration, rats were challenged with METH (1 mg / kg, i.p.), and then their locomotor activity was measured every 15 min for 120 min. The locomotor activity was detected and recorded automatically using the locomotor activity chamber crossed by 144 infrared beams (Melquest Co., Ltd., Toyama) in a blind fashion when animals interrupted the beams.
The time course data for the locomotor activity counts were analyzed statistically by a two-way analysis of variance (ANOVA) with time as the repeated measure, followed by the Bonferroni post hoc test. Total locomotor activity counts were analyzed by a regular twoway ANOVA, with sensitization (non-sensitized and METH-sensitized) × drug (vehicle and TFB-TBOA), followed by the Bonferroni post hoc test. Differences with P<0.05 were considered significant.
The effect of i.c.v. administration of TFB-TBOA on the expression of METH-induced behavioral sensitization was investigated. Figure 1 shows the time course of locomotor activity elicited by the challenge with METH (1 mg / kg) in the rats that received saline (nonsensitized) or 2 mg / kg METH (METH-sensitized) for 5 consecutive days. Two-way ANOVA with time as the repeated measure indicated significant effects for group (F 3,154 = 9.10, P<0.001) and group × time interaction (F 21,154 = 3.24, P<0.001). The Bonferroni post hoc test showed significant differences between non-sensitizedvehicle and METH-sensitized-vehicle groups at 30 min (P<0.05) and 45 min (P<0.05), METH-sensitizedvehicle and METH-sensitized-TFB-TBOA groups at 15 min (P<0.01) and 30 min (P<0.05) after the METH challenge. On the other hand, there was no significant difference between the non-sensitized-vehicle and nonsensitized-TFB-TBOA groups. Figure 2 shows total locomotor activity counts for 120 min. Two-way ANOVA showed significant effects for sensitization (F 1,22 = 19.3, P<0.001) and drug (F 1,22 = 5.94, P<0.05). The Bonferroni post hoc test indicated that TFB-TBOA significantly enhanced the total locomotor activity in METH-sensitized rats (P<0.05), but not non-sensitized rats. These results indicated that repeated METH treatments induced behavioral sensitization, and that i.c.v. administration of TFB-TBOA to METH-sensitized, but not non-sensitized, rats 10 min before the METH challenge facilitated the behavioral sensitization.
A body of evidence suggests that the glutamate receptors are implicated in the expression of behavioral sensitization to amphetamines, although there are also conflicting results. Systemic administration of several α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)-receptor antagonists inhibited the expression of behavioral sensitization, although some AMPAreceptor antagonists were ineffective (1). Intra-nucleus accumbens administration of N-methyl-D-aspartate (NMDA)-receptor antagonists was reported to prevent the expression of behavioral sensitization (9) , although systemic administration of many NMDA-receptor antagonists did not (1) . On the other hand, since TFB-TBOA could elevate the extracellular glutamate level by blocking glutamate uptake (8) , it is suggested that the functional activation of all of the glutamate receptor subtypes may induce facilitation of the expression of behavioral sensitization. Thus, the present results further support the notion of the roles of the glutamatergic system in the expression of METH-induced behavioral sensitization.
Among the glutamate transporter subtypes, a glial type GLT-1 is reported to play the most important role in maintaining low extracellular glutamate levels (3). We recently reported that gene transfer of GLT-1 into the nucleus accumbens attenuated methamphetamineconditioned rewarding effects (10) . Taken together, we consider that a glial glutamate transporter, GLT-1, might be largely involved in the facilitative effects of TFB-TBOA in the present experiments. Additional investigations are needed to fully explore this.
It has been shown that the mesolimbic dopaminergic system could be modulated by glutamatergic systems. Electrophysiological and in vivo microdialysis studies showed that glutamate excites the mesolimbic dopaminergic neurons (11) . In addition, increased locomotor activity as a result of glutamate injection into the ventral tegmental area (11) or nucleus accumbens (12) was blocked by dopamine receptor antagonists. These findings provide evidence that glutamatergic systems in the ventral tegmental area and nucleus accumbens contribute to the METH-induced locomotor activation by affecting the mesolimbic dopaminergic neurons. It was shown that a glutamate transporter inhibitor, Ltrans-pyrrolidine-2,4-dicarboxylic acid (L-trans-PDC), increased extracellular glutamate as well as dopamine levels in the striatum (13) . Taken together, it is conceivable that inhibition of glutamate transporters by TFB-TBOA activates glutamatergic systems in areas such as the ventral tegmental area and nucleus accumbens, and this further enhances activation of the mesolimbic dopaminergic system, to facilitate the expression of METH-induced behavioral sensitization. This is supported by the finding that intra-nucleus accumbens administration of a glutamate-transporter inhibitor Ltrans-PDC with a D 1 dopamine-receptor agonist could elicit locomotor activation in amphetamine-sensitized, but not saline-treated, rats (14) . Furthermore, perfusion of TFB-TBOA in the nucleus accumbens dramatically elevated the extracellular glutamate level within the nucleus accumbens of METH-sensitized, but not salinetreated, rats (our unpublished data). These findings suggest that the expression of METH-induced behavioral sensitization may be due to the enhanced glutamatergic system, at least in part, in the nucleus accumbens, which is usually masked by the function of glutamate transporters.
Recently, it was reported that repeated administration of a glutamate transporter inhibitor alone into the ventral tegmental area induced a behavioral sensitization-like locomotor activating effect of amphetamine (15) , suggesting that the inhibition of glutamate transporters in the ventral tegmental area produces neuroadaptations necessary to induce behavioral sensitization. To assess whether the glutamate transporters is implicated in the development of METH sensitization, further investigations will be needed.
In summary, we have shown that i.c.v. administration of a potent glutamate transporter inhibitor TFB-TBOA facilitates the expression of METH-induced behavioral sensitization, without affecting acute locomotor activation. These findings suggest that central glutamate transporters play an inhibitory role in the expression of METH-induced behavioral sensitization by decreasing the elevated extracellular glutamate level. The present study may provide a new strategy for preventing drug addiction.
